235 East 42nd Street
About Pfizer Inc.
Imagine touching the lives of people everywhere. Imagine reaching beyond the ordinary and impacting something greater than the bottom line. Imagine influencing some of the most critical issues facing healthcare today.
At Pfizer Global Research & Development (PGRD), Pfizer’s visionary discovery and development division and the largest research-based biomedical and pharmaceutical company in the world, we're not content waiting to witness the evolution of our industry. Instead, we’re driven by science, building on our current successes and capabilities, playing a critical role in developing the most compelling story of scientific discoveries.
To date, PGRD has brought to market a wide range of medicines, such as Lipitor® (atorvastatin calcium), Zithromax® (azithromycin), Viracept® (nelfinavir mesylate), Zoloft® (sertraline hydrochloride), Viagra® (sildenafil citrate), and our newest smoking cessation medicine, Chantix® (varenicline). And, today, with a broad research pipeline that spans many therapeutic areas, we are determined to bring even more cures to the marketplace.
But there is much more work to be done and we can’t do it alone. We’re always seeking those who share our belief that science can improve our world, that by working together we can bring exciting new therapies to patients on a global scale and forever change the way we improve the health and well-being of all people.
Why Join Pfizer?
Pfizer offers the opportunity to work on promising research, access to unparalleled resources and world-class facilities, and the chance to work with some of the brightest and most driven individuals in the pharmaceutical industry.
At Pfizer, we build our success on the innovation, skills, and entrepreneurial spirit of each of our colleagues. As an integral member of our team, you'll find myriad opportunities to assert your professional independence as you generate results that will advance our ultimate goal of creating life-enhancing therapies.
In addition to creating the environment for innovation, our values have led to numerous corporate awards acknowledging excellence in many domains - with investors, our business partners, and our employees. We've been praised as “One of the 100 Best Companies for Working Mothers” by Working Mother® Magazine (9/07), honored with “The Best Employers for Healthy Lifestyles 2007 Award” by the National Business Group on Health (5/07), and awarded by the Women's Business Enterprise National Council on its annual listing of America's Top Corporations for Women's Business Enterprises (3/07).
At PGRD, your success is critical to our success. PGRD offers world-class career opportunities, directing resources and time that result in a high-level scientific professional track. Our employees and external rankings with the leading authorities attest to the fact that PGRD is one of the best companies to work for - where you choose a lifestyle - not just a job.
• La Jolla, CA
Located north of downtown San Diego, La Jolla boasts southern California's most beautiful and majestic coastline, with an abundance of cultural, outdoor recreation, and big city activities. Home to Salk Institute and Scripps Research Institute - two renowned academic institutions - and many major biotechnology and telecommunications firms, La Jolla offers a rich environment for both scientists and engineers.
• New London and Groton, CT
Located on the southeastern Connecticut seashore in a historical New England vacation area known for its seafood, easy pace of living, and nautically related recreational activities. It's also within reasonable driving distance to a wealth of greater academic institutions, and within a couple of hours of Boston and New York.
• St. Louis, MO
Known as the Gateway to the West, St. Louis is a diverse, vibrant metropolitan area of 2.5 million, with a broad-based economy. Residents enjoy professional sports teams, a world-class symphony orchestra, botanical gardens, and numerous other outdoor activities. Additionally, scientists have the opportunity to collaborate with researchers at Washington University School of Medicine.
• Sandwich, UK
Sandwich, once a major port in England but now 2 miles from the sea, is one of the best-preserved Medieval towns in the UK, with its old town walls and "Kent Peg" roof houses. Situated close to the city of Canterbury and only 80 miles from London, the area is steeped in history and is ideal for those who enjoy water sports. The rail links across the English Channel also mean that you can be in France within an hour, providing access to the whole of Europe.
At PGRD, we celebrate the talents and diversity of our employees. We respect our employees' lives and provide a multitude of resources and supports to help foster a work/life balance. Also, in addition to our outstanding career opportunities and quality of life, we offer a wide array of topnotch and leading-edge benefits, competitive compensation, and exceptional long-term financial rewards designed to ensure your well-being and financial security. We offer you choices so you can craft a plan that meets your individual and family needs.
Your talent can change the world. Join us.
To learn more about our people, our products, and our plans for the future, visit www.pfizer.jobs
We’re proud to be an equal opportunity employer and welcome applications from people with different experiences, backgrounds, and ethnic origins.
Founder: Charles Pfizer
CEO: Ian C. Read
CMO: Freda C. Lewis-Hall, M.D., DFAPA
CFO: Frank D’Amelio
Please click here for clinical trial information.
For more information, visit
www.pfizer.com and follow us on www.twitter.com/Pfizer.
Tweets by Pfizer
Innovating for Healthier Lives
3727 articles with Pfizer Inc.
NIVESTYM™, a biosimilar to Neupogen® (filgrastim), is Pfizer’s fourth biosimilar to be approved by the FDA.
It was reported today that U.S.-based Merck & Co. will lower the price of some of its drug. It appears to be rippling through the industry, largely in an attempt to stay out of the way of Trump’s attack-tweets.
Pfizer And Lilly Announce Positive Top-Line Results From Phase 3 Trial Of Tanezumab For The Treatment Of Osteoarthritis (OA) Pain
Tanezumab is also being evaluated for chronic low back pain (CLBP) and cancer pain (due to bone metastases).
ViiV Healthcare with Pfizer Inc. and Shionogi Limited as shareholders, will be presenting over 20 abstracts, including data from the landmark GEMINI 1 & 2 clinical trials, at the 22nd International AIDS Conference (AIDS 2018), 23-27 July 2018, in Amsterdam, The Netherlands.
Vyriad Announces Collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer to Evaluate Oncolytic Virus, Voyager-V1, in Combination with Anti-PD-L1 Antibody, Avelumab, in Phase 1 Clinical Study for Metastatic Colorectal Cancer
Voyager-V1 is being administered to inflame the tumors, and avelumab has been shown to release the suppression of the T cell-mediated antitumor immune response in preclinical models.
Pfizer and Eli Lilly released results from its 16-week Phase III clinical trial in patients with osteoarthritis (OA) pain receiving a subcutaneous dose of tanezumab. The drug hit all three co-primary endpoints.
7/18/2018Swiss pharma giant Novartis is halting planned price increases on its medications after President Donald Trump took Pfizer to task over price hikes earlier this month. Pfizer agreed to roll back its price increases last week.
Phase 3 lead-in study initiated following completion of the transfer of Spark Therapeutics’ hemophilia B gene therapy program to Pfizer
Four months after filing a supplemental New Drug Application with the U.S. Food and Drug Administration, Astellas and Pfizer snagged regulatory approval for Xtandi as a treatment for non-metastatic Castration-Resistant Prostate Cancer (CRPC).
U.S. FDA Approves XTANDI® (enzalutamide) for the Treatment of Men with Non-Metastatic Castration-Resistant Prostate Cancer (CRPC)
First and Only Oral Treatment FDA-Approved for Both Non-Metastatic and Metastatic CRPC
President Trump was able to declare a small victory in the arena of drug pricing earlier this week when Pfizer opted to delay its second price-hike of the year. Other companies though have not followed suit and have gone through with price increases for their drugs.
--U.S. FDA Approves XTANDI® (enzalutamide) for the Treatment of Men with Non-Metastatic Castration-Resistant Prostate Cancer (CRPC)--
First and Only Oral Treatment FDA-Approved for Both Non-Metastatic and Metastatic CRPC.
Pfizer Inc. (NYSE:PFE) today announced it will organize the company into three businesses: a science-based Innovative Medicines business which will now include biosimilars and a new hospital business unit for anti-infectives and sterile injectables.
Pharma giant Pfizer will reorganize itself into three different business units that will include an innovative medicines business that includes a new hospital-focused segment for anti-infectives and sterile injectables.
President Donald Trump was able to claim a victory in the drug pricing wars after Pfizer announced it would walk back the price increase of 40 prescription medications announced earlier this month.
President Donald Trump used the power of his Twitter feed to call out and condemn pharma giant Pfizer after that company increased the price of a number of its prescription medications by nearly 10 percent.
Tmunity Therapeutics, Inc. today announced the appointment of Christina Coughlin, MD, PhD, as Chief Medical Officer and Executive Vice President.
Allogene Therapeutics announced the implementation of its Scientific Advisory Board (SAB). The SAB is made up of five leaders in oncology, immunology, drug discovery and development, and will consult on strategic and scientific matters.
7/6/2018Gilead may be down, but at least one analyst thinks the company is poised for a turnaround.
The president’s predictions for lower drug prices fell on deaf ears at pharma giant Pfizer as it was reported that the company increased the price of 40 of its most popularly-prescribed medications by nearly 10 percent.